HTB: no. 1/2 (January/February 2022)
7 February 2022. Related: Editorial.
2022
i-Base appeal: please support i-Base with £5 or £10 a month
7 February 2022. Related: Editorial.
CROI 2022 to only be virtual: programme online
7 February 2022. Related: Conference reports.
US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
7 February 2022. Related: Antiretrovirals.
Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
7 February 2022. Related: Antiretrovirals.
Drug resistance profile of integrase inhibitors when treating HIV-2
7 February 2022. Related: Drug resistance.
HIV-associated reductions in telomere length are stopped by effective ART
7 February 2022. Related: Coinfections and complications, Basic science and immunology, Ageing and life expectancy.
BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections
7 February 2022. Related: Guidelines.
UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19
7 February 2022. Related: COVID-19: investigational drugs, COVID-19.
IDSA update COVID-19 guidelines (January 2022)
7 February 2022. Related: COVID-19: guidelines, COVID-19.
i-Base vacancy: HIV treatment advocate and information officer
7 February 2022. Related: Job vacancies.
EACS HIV Summer School 2022: Applications are open
7 February 2022. Related: Other news.
HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)
7 February 2022. Related: PDFs.